NEW YORK, March 19 (Reuters) - Johnson & Johnson is running its Tylenol manufacturing at maximum capacity in North America in order to contend with surging demand for the product due to the fast-spreading coronavirus outbreak, the head of its consumer health unit’s North American operation said in an interview on Thursday.
“We’re running it at all-out, maximum capacity,” said Kathleen Widmer, group chairman for North America of Johnson & Johnson Consumer Health. Widmer said that they had added crews and were maximizing the use of equipment and capacity in plants in Puerto Rico and Pennsylvania where the drug is produced.
Widmer also said the company is not experiencing a shortage of the raw materials it needs to make Tylenol. (Reporting by Michael Erman, Editing by Franklin Paul)